CD24 recombinant proteins and antibodies

Signal transducer CD24 (CD24) is a small molecular weight glycoprotein highly glycosylated and expressed on various immune cell types such as B cells, T cells, and dendritic cells. It plays a crucial role in immune responses, especially in tumor immune evasion. CD24 interacts with receptors like Siglec-10, promoting immunosuppressive effects in tumor cells, thus reducing the immune system’s ability to recognize and eliminate tumor cells. As a result, CD24 is considered a promising target in cancer immunotherapy. Currently, CD24 is a research hotspot in cancer immunotherapy, with numerous pharmaceutical companies and research institutions actively developing treatments targeting CD24. Strategies for targeting CD24 primarily focus on monoclonal antibodies, vaccine therapies, and cell therapies.

In terms of ongoing drug development, several biopharmaceutical companies are developing monoclonal antibodies targeting CD24. For example, certain monoclonal antibodies can block the interaction between CD24 and Siglec-10, enhancing the immune response against tumor cells. Additionally, vaccine research is focused on inducing antibodies against CD24 to improve tumor cell recognition and elimination. Cell therapy approaches are also being explored, where immune cells are modified to specifically target and attack CD24-expressing tumor cells. As for key players entering this field, major pharmaceutical companies like Novartis, Merck, and Acri have begun focusing on CD24-targeted therapies, investing heavily in research and development. These companies aim to offer new therapeutic options for cancer patients, particularly in cases where traditional therapies have limited effectiveness.

To assist in the development of CD24 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD24 targets. Products include active proteins, reference antibodies, and flow-cytometry-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD24 biotherapy, DIMA BIOTECH has also prepared a CD24 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD24 lead molecules, and customers can get the molecules for functional evaluation and verification the next day.